ERC receives a positive Opinion to commence a paediatric investigation plan(clinical trial) from the European Medicines Agency.

ERC receives a positive Opinion to commence a paediatric investigation plan(clinical trial) from the European Medicines Agency for treatment of children between 3 and 18 years of age with relapsing malignant glioma with its product Gliovac/ERC1671/SITOIGANAP.

For more info please contact us.